Active Ingredient(s): Palonosetron
FDA Approved: * July 25, 2003
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Aloxi Overview

Palonosetron (INN, trade name Aloxi) is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is used for the control of delayed CINV—nausea and vomiting and there are tentative data to suggest that it may be more effective than granisetron.[1] Palonosetron is administered intravenously, as a single dose, 30 minutes before chemotherapy,[2] or as a single oral capsule one hour before chemotherapy.&am...

Read more Aloxi Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Aloxi Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Capsule: 0.5mg
  • Injection: 0.075mg/1.5ml (0.05mg/ml), 0.25mg/5ml, 0.25mg/5ml (0.05mg/ml)
  • Solution: 0.25mg/5ml, 0.25mg/5ml (0.05mg/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Aloxi: (5 results)

Sorted by National Drug Code
  • 62856-797 Aloxi .25 mg/5ml Intravenous Injection by Eisai, Inc
  • 62856-798 Aloxi .075 mg/1.5ml Intravenous Injection by Eisai, Inc
  • 62856-799 Aloxi 0.5 mg (Palonosetron Hydrochloride 0.056 mg) Oral Capsule by Eisai
  • 69639-103 Aloxi .05 mg/ml Intravenous Injection by Helsinn Therapeutics (U.s.), Inc.
  • 69639-104 Aloxi .5 mg/.5mg Oral Capsule by Helsinn Therapeutics (U.s.), Inc.

Other drugs which contain Palonosetron or a similar ingredient: (3 results)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 17 April 2021.

We are committed to your privacy.

Copyright © 2005-2021 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA